Shenzhen Yhlo Biotech Co., Ltd. (688575.SH) announced that it recently received a medical device registration certificate issued by the National Medical Products Administration. The product, named "Human Chorionic Gonadotropin and β-Subunit Assay Kit (Chemiluminescence Method)," is designed for the quantitative in vitro determination of human chorionic gonadotropin and β-subunit levels in human serum and/or plasma.
This kit is primarily used for dynamic monitoring of malignant tumor patients to assist in evaluating disease progression or treatment efficacy. However, it cannot serve as a basis for early diagnosis or confirmation of malignant tumors and is not intended for cancer screening in the general population.
Comments